ArticleAIDS and behavior2025
A Universal Approach to Educating Patients with HIV about Long-Acting Injectable Treatment for HIV.
Article in AIDS and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- What Do People with HIV Want to Know About Long-Acting Injectable Cabotegravir/Rilpivirine?AIDS and behavior · 2026Article
- Long-Acting Injectable Antiretroviral Drugs for Pregnant and Breastfeeding Women: Current Advances, Challenges, and Future Directions.Current HIV/AIDS reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Long-acting injectable antiretroviral treatment (LAI ART) has the potential to transform HIV care and reduce HIV-related health inequities in achieving and maintaining viral suppression. However, without a plan for equitable roll-out of LAI ART, new pharmacological innovations in HIV treatment and prevention risk further deepening health disparities. This study delineates a process for providing universal LAI ART education to people with HIV (PWH) at an urban outpatient infectious disease clinic and documents the outcomes of these efforts. We compared the number and proportion of patients with HIV educated about injectable cabotegravir-rilpivirine (iCAB/RPV) and, among those educated, the number and proportion of patients interested in learning more about iCAB/RPV under a selective education model compared to a universal education model, disaggregated by race/ethnicity, sex, and age. We used a Chi-sq test to estimate p-values for the difference in proportions. The universal compared to selective education approach resulted in a larger proportion of clients educated and a greater proportion of people educated reporting interest in LAI ART. Slight differences observed between those never versus ever educated in the selective education were absent after the adoption of a universal education approach. Reasons for disinterest -- including fear of injections, not interested in more frequent clinic visits, and content with oral ART regimen -- did not differ across educational approaches. Our programmatic data offers preliminary evidence that a universal education approach can support and enhance equitable roll-out of LAI ART. Most patients with HIV are interested in learning more about LAI ART.
Indexed as
Identifiers
40029583What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.